RECORMON 2000

Indications

• Asthma
• Chronic Obstructive Pulmonary Disease (COPD)
• Hypertension
• Heart Failure
• Cardiac Arrhythmias

Dosage

Children: Refer to the BNF for Children for appropriate dosing

Adults: Refer to the BNF for specific dosing guidelines based on the condition being treated and the formulation of the drug used.

Mechanism of action

Beta-adrenergic agonists stimulate beta-adrenergic receptors, leading to increased intracellular cAMP levels, which causes relaxation of bronchial smooth muscle and dilation of the airways. This mechanism is particularly important in the treatment of asthma and COPD, where airway constriction is a major issue. Beta-blockers, on the other hand, inhibit the effects of catecholamines on beta receptors, resulting in decreased heart rate and myocardial contractility, which is beneficial in managing hypertension and certain types of cardiac arrhythmias.

Pharmacodynamics

The pharmacodynamics of beta drugs vary depending on whether they are agonists or antagonists. Agonists lead to a dose-dependent bronchodilation and increased heart rate, while antagonists decrease heart rate and myocardial oxygen demand. The effects of these drugs can be influenced by patient-specific factors such as receptor sensitivity, presence of comorbid conditions, and concurrent medications.

Pharmacokinetics

The pharmacokinetics of beta drugs can differ substantially. Agonists are typically rapidly absorbed and distributed, with onset of action occurring within minutes. They may have short half-lives, necessitating multiple doses throughout the day. Beta-blockers, in contrast, may have longer half-lives and can be administered once or twice daily. Metabolism usually occurs in the liver, and renal excretion is common for both classes, affecting their dosing in patients with renal impairment.

Interactions

• betablockers, selective + aminophylline: Severe (increases risk of bronchospasm)
• dacomitinib + betablockers, selective: Severe (increases exposure)
• mexiletine + betablockers, selective: Severe (increases risk of cardiovascular adverse effects)
• betablockers, selective + theophylline: Severe (increases risk of bronchospasm)
• beta 2 agonists + linezolid: Severe (increases risk of elevated blood pressure)
• mao-b inhibitors + beta: Severe (increases risk of severe hypertension)
• verapamil + betablockers, non-selective: Severe (increases risk of cardiovascular adverse effects)
• cobicistat + beta: Severe (increases exposure)
• dacomitinib + betablockers, non-selective: Severe (increases exposure)
• idelalisib + beta: Severe (increases exposure)

Indications

• Anemia due to chronic kidney disease
• Anemia in cancer patients receiving chemotherapy
• Anemia related to HIV infection
• Anemia in patients with myelodysplastic syndromes
• Anemia associated with chronic inflammatory diseases

Dosage

Children: Refer to the BNF for Children for appropriate dosing information based on the indication and patient's age.

Adults: Refer to the specific product information and guidelines for dosing recommendations based on the indication, as doses can vary significantly.

Mechanism of action

Erythropoietin binds to specific receptors on erythroid progenitor cells in the bone marrow, activating intracellular signaling pathways that lead to increased proliferation and differentiation of these cells into mature red blood cells. This process also inhibits apoptosis of erythroid progenitors, thus enhancing red blood cell production.

Pharmacodynamics

The primary pharmacodynamic effect of erythropoietin is the stimulation of erythropoiesis, leading to increased hemoglobin levels and improved oxygen-carrying capacity of the blood. It acts by promoting the survival and proliferation of erythroid progenitor cells, resulting in enhanced production of red blood cells. The onset of action is typically observed within a few days, with peak effects occurring within 1 to 2 weeks after administration.

Pharmacokinetics

Erythropoietin has a relatively short half-life, generally ranging from 4 to 13 hours, depending on the formulation and route of administration. It is primarily eliminated by the kidneys, with a significant portion being excreted in the urine. The drug's bioavailability varies based on the method of administration; subcutaneous administration may have lower bioavailability compared to intravenous routes. The pharmacokinetics can be affected by factors such as renal function, age, and concurrent medications.

Contra-indications

• Uncontrolled hypertension
• Hypersensitivity to erythropoietin or any component of the formulation
• Pure red cell aplasia due to anti-erythropoietin antibodies

Adverse effects

• Hypertension
• Headache
• Fatigue
• Dizziness
• Nausea
• Diarrhea
• Injection site reactions
• Increased risk of thromboembolic events

Interactions

• Increased risk of hypertension with concurrent use of other erythropoiesis-stimulating agents
• Potential interactions with other medications that affect blood pressure

Precautions

• Monitor hemoglobin levels regularly to avoid excessive increases
• Use with caution in patients with a history of cardiovascular disease
• Avoid rapid increases in hemoglobin levels
• Assess for underlying causes of anemia before initiating therapy

Pregnancy

Erythropoietin is classified as Category C. It should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Breast-feeding

It is not known whether erythropoietin is excreted in human milk. Caution should be exercised when administering to nursing mothers.

Storage

Store vials in the refrigerator at 2°C to 8°C. Do not freeze. Protect from light. Once opened, use within 28 days if stored in a refrigerator.

Formulations

• Injection solution in vials
• Pre-filled syringes